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Purpose: Cinacalcet is effective for treating refractory secondary hyperparathy-
roidism (SHPT), but little is known about the response rates and clinical factors 
influencing the response. Materials and Methods: A prospective, single-arm, 
multi-center study was performed for 24 weeks. Cinacalcet was administered to 
patients with intact parathyroid hormone (iPTH) level greater than 300 pg/mL. 
Cinacalcet was started at a dose of 25 mg daily and titrated until 100 mg to 
achieve a serum iPTH level <300 pg/mL (primary end point). Early response to 
cinacalcet was defined as a decrease of iPTH more than 50% within one month. 
Results: Fifty-seven patients were examined. Based on the magnitude of iPTH 
decrease, patients were divided into responder (n=47, 82.5%) and non-responder 
(n=10, 17.5%) groups. Among the responders, 38 achieved the primary end point, 
whereas 9 patients showed a reduction in serum iPTH of 30% or more, but did 
not reach the primary end point. Compared to non-responders, responders were 
significantly older (p=0.026), female (p=0.041), and diabetics (p<0.001). Addi-
tionally, early response was observed more frequently in the responders (30/47, 
63.8%), of whom the majority (27/30, 90.0%) achieved the primary end point. 
Multivariate analysis showed that lower baseline iPTH levels [odds ratio (OR) 
0.96, 95% confidence interval (CI) 0.93-0.99], the presence of diabetes (OR 
46.45, CI 1.92-1125.6) and early response (OR 21.54, CI 2.94-157.7) were signif-
icant clinical factors affecting achievement of iPTH target. Conclusion: Cinacal-
cet was effective in most hemodialysis patients with refractory SHPT. The pres-
ence of an early response was closely associated with the achievement of target 
levels of iPTH.
Key Words:   Cinacalcet, end-stage renal disease, hemodialysis, parathyroid hor-
mone, secondary hyperparathyroidism 
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life were also observed with cinacalcet treatment in patients 
with end stage renal disease.17 With these findings, the use 
of cinacalcet could be an attractive therapeutic option, but 
little is known about the response rates and clinical factors 
influencing its therapeutic response.
This study aimed to evaluate the efficacy and safety of 
cinacalcet in hemodialysis patients with refractory SHPT. 
And clinical factors influencing therapeutic response to 
cinacalcet were also investigated. 
MATERIALS AND METHODS
　　　
Participants and design
This study was designed as a prospective, open-label, sin-
gle-arm, multi-center study in Korea, consisting of a 
4-week pretreatment observation period and a 24-week 
treatment period, from November 2009 to October 2010. A 
total of 67 patients with SHPT were recruited from seven 
university hemodialysis units (12, 15, 10, 10, 5, 5, and 10 
subjects were included in each hospital). All patients under-
went regular 4-hour hemodialysis treatments three times 
per week with a mean dialysate calcium concentration of 
3.0 mEq/L (=6 mg/dL). Cinacalcet was administered to pa-
tients whose serum albumin-corrected calcium concentra-
tion was greater than 9.0 mg/dL and had refractory hyper-
parathyroidism, defined as iPTH level was greater than 300 
pg/mL for two consecutive measurements, before study ini-
tiation, despite treatment with vitamin D and/or phosphate 
binders of any type. The interval between the two tests was 
more than 3 months. Intact PTH levels were measured by 
immunoradiometric assay (Nichols Institute Diagnostics, 
San Clemente, CA, USA). There was no upper limit of se-
rum iPTH level for enrollment consideration. Cinacalcet 
was started at 25 mg per day orally. During the initial 
2-month dose titration period, serum iPTH, albumin-cor-
rected calcium and phosphorus levels were measured every 
2 weeks. The dose of cinacalcet was increased up to 100 
mg if serum iPTH was over 300 pg/mL and albumin-cor-
rected calcium level was over 8.5 mg/dL. When the albu-
min-corrected calcium level decreased to 8.0 mg/dL, cina-
calcet was discontinued or the dose was titrated down to 
avoid hypocalcemia. Thereafter, cinacalcet was maintained 
for 4 months (maintenance period) to determine its efficacy 
and safety. Serum calcium, phosphorus, and iPTH levels 
were measured every 4 weeks during the maintenance peri-
od. Serum calcium was corrected with the serum albumin 
INTRODUCTION
Secondary hyperparathyroidism (SHPT) is a common com-
plication of dialysis as a consequence of decreased renal 
function, vitamin D deficiency, and impaired mineral me-
tabolism.1,2 According to previous data, disorders of calci-
um, phosphate, and vitamin D homeostasis, as well as in-
creased intact parathyroid hormone (iPTH) concentrations 
are associated with multiple comorbidities including renal 
osteodystrophy, anemia with erythropoietin resistance, vas-
cular calcification, and cardiovascular disease. In fact, dis-
ordered calcium phosphorus homeostasis and resultant 
SHPT cause significant long-term morbidity and mortality 
in dialysis patients.3-5 Since a better control of SHPT is as-
sociated with a more favorable prognosis, optimal manage-
ment of SHPT may be one of the principal goals in manag-
ing hemodialysis patients.
Treatment modalities of SHPT have evolved based upon 
new insights into the pathogenesis and clinical features of 
this disorder. Because of the interdependence of calcium, 
phosphate, vitamin D, and iPTH, pharmacological combina-
tory treatment is often necessary in patients with advanced 
renal dysfunction.4,6,7 Despite combined treatment of SHPT 
with dietary modification, phosphate binders and vitamin D 
analogs, however, these therapeutic interventions are not al-
ways successful,7-9 furthermore, these treatment could ag-
gravate the calcium and phosphorus disturbance.10,11 There-
fore, cinacalcet is increasingly prescribed to treat SHPT in 
patients with renal impairment.6
Cinacalcet, a second generation calcimimetic, binds to 
and modulates the calcium sensing receptor (CasR) on the 
parathyroid gland which increases its sensitivity to extracel-
lular calcium, thereby suppressing PTH secretion without 
exacerbating hyperphosphatemia or hypercalcemia.3,4,12,13 
Several randomized controlled studies have demonstrated 
the efficacy of cinacalcet in lowering iPTH, calcium, and 
phosphorus levels compared to conventional treatment reg-
imens.2,4,13,14 For instance, Moe, et al.10 demonstrated the 
long-term efficacy of cinacalcet for control of SHPT, and 
Lucchi, et al.15 recently showed that earlier use of cinacalcet 
could provide better iPTH control in dialysis patients. In 
addition to its effects on iPTH and mineral metabolism, 
cinacalcet has also been shown to reduce the risk of para-
thyroidectomy, fractures, and cardiovascular hospitaliza-
tion.5,16 Moreover, significant reduction of darbepoetin re-
quirements and improvement of health-related quality of 
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RESULTS
 
Of the 67 patients initially included in the study, 10 patients 
were excluded for the following reasons: one patient under-
went kidney transplantation before starting cinacalcet, two 
patients died, and seven patients were dropped out according 
to the treating physician’s discretion (Fig. 1). The remaining 
57 patients had a mean age of 50.9±12.5 years, and median 
duration of dialysis dependence of 11.1 years. At enrollment, 
55/57 (96%) patients were receiving phosphate-binding 
agents, 25/57 (43.8%) were receiving vitamin D sterols, and 
32/57 (45.6%) were not being treated with vitamin D agents 
concentration when the serum albumin level was less than 
4.0 g/dL [corrected calcium= measured calcium+(4-mea-
sured serum albumin)×0.8].18 In this study, to avoid severe 
hypocalcemia, the types and doses of phosphate binders 
were flexibly adjusted according to the treating physician’s 
discretion. However, the dose of vitamin D was fixed or al-
lowed only to reduce. The study was approved by the med-
ical ethics committee of each hospital, and all participants 
provided written informed consent. All clinical investiga-
tions have been conducted according to the principles ex-
pressed in the Declaration of Helsinki.
Parathyroid gland measurements
To assess parathyroid gland size, a computed tomography 
of the neck was performed upon study initiation. Using a 
standard protocol, contiguous axial 0.5- to 1-mm images 
were acquired after the intravenous (IV) administration of 
contrast material, with a small field of view from the hyoid 
bone down to the carina. Non-enhanced images were simi-
larly obtained. The detected parathyroid glands were mea-
sured in the transverse, anterior-posterior, and longitudinal 
dimensions; the longest one was used in this study.  
Study end point
The primary end point was the decrease of serum iPTH lev-
els to 300 pg/mL or less during the study period. The sec-
ondary end point was a reduction of serum iPTH levels by 
at least 30% or more from baseline levels. An early re-
sponse was defined as a decrease in iPTH levels by greater 
than 50% from the baseline within 1 month of cinacalcet 
initiation.
Statistical analysis
All laboratory parameters are expressed as mean±SD when 
normally distributed, or median with ranges when values 
were not normally distributed. Differences between groups 
were analyzed by Fisher’s exact test for categorical data, 
the independent t-test for continuous parameters, and the 
Mann-Whitney U test for continuous nonparametric data. A 
repeated measures analysis of variance (ANOVA) linear 
model was used to compare laboratory parameters after 
treatment within each group. In addition, Pearson’s correla-
tion analysis was used to elucidate the relationship between 
iPTH levels and sizes of the parathyroid gland. Logistic re-
gression was used to identify factors that predicted a signif-
icant reduction in iPTH levels. p values <0.05 were consid-
ered statistically significant.
Fig. 1. Flow diagram of patient recruitment and progress. 
Fig. 2. Parathyroid gland size and serum iPTH levels. Maximal size of para-
thyroid gland detected on neck CT was highly correlated with serum iPTH 
levels (r=0.521, p<0.001). iPTH, intact parathyroid hormone.
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lated with the serum iPTH level (r=0.521, p<0.001) (Fig. 2). 
Efficacy
The primary end point was achieved in 38 (66.7%) patients. 
(because of hypercalcemia, hyperphosphatemia, or both) 
(Table 1). The type of vitamin D treatment was IV calcitriol 
and median dose was 2.8 mcg per week. The maximal 
length detected for the parathyroid gland was highly corre-
Table 1. Baseline Characteristics of All Patients (n=57)
Responder (n=47, 82.5%)
Non-responder
(n=10, 17.5%)
Total
(n=57)Primary end point 
(n=38, 80.8%)
Secondary 
end point only 
(n=9, 19.2%)
All 
(n=47, 82.5%)
Age (yrs)†,‡   54.5±12.1   44.9±12.6   52.6±12.7  43.0±7.7   50.9±12.5
Male, n (%)† 14 (36.8)   2 (22.2)  16 (34.0)   7 (70.0) 23 (40.4)
Body mass index (kg/m2) 22.2±2.5 24.3±3.2 22.6±2.8  21.6±3.2 22.0±3.0
Diabetes, n (%)† 12 (31.6)   1 (11.1)  13 (27.7) 0 (0.0) 13 (22.8)
Duration of hemodialysis (yrs)*    10.6 (1.0-26.2)     11.4 (1.3-27.5)     10.8 (1.0-27.5)     11.4 (3.0-13.4)     11.1 (1.0-27.5)
MBP (mm Hg)‡   94.5±14.5 105.7±13.5   96.7±14.7  99.6±9.3   97.2±13.9
Previous vascular disease, n (%)
    Coronary artery disease 10 (26.3)   3 (33.3)  13 (27.7)   3 (30.0) 16 (28.1)
    Peripheral artery disease 2 (5.3) 0 (0.0)  2 (4.3) 0 (0.0) 2 (3.5)
    Cerebrovascular accident   8 (21.1)   2 (22.2)  10 (21.3)   2 (20.0) 12 (21.1)
Maximal size of detected PTG (mm)‡ 14.2±5.6 19.6±8.1 15.3±6.5  15.9±7.5 15.4±6.6
Laboratory measurements
    Hemoglobin (g/dL) 11.5±2.0 10.2±1.7 11.2±2.0  11.2±1.3 11.2±1.6
    Blood urea nitrogen   66.8±21.0   65.9±24.0   66.7±21.4    62.5±24.9   66.0±24.9
    Creatinine 10.6±2.5   9.9±3.6 10.5±2.7  10.5±2.6 10.5±2.7
    Total cholesterol 153.3±37.9 142.4±29.6 151.3±36.5  150.9±49.7 151.2±38.6
    LDL-cholesterol   81.7±31.5   73.9±26.3   80.4±30.6    82.9±40.9   80.8±32.1
    HDL-cholesterol   48.7±13.3   42.6±10.7   47.6±12.9    52.8±17.5   48.5±13.8
    Triglyceride 103.5±61.4 137.1±45.2 109.9±59.6    96.5±32.2 107.6±50.1
    Corrected calcium (mg/dL) 10.0±0.8 10.0±0.8 10.0±0.8  10.6±1.2 10.1±0.9
    Phosphorus (mg/dL)   5.1±1.5   6.3±1.7   5.3±1.6    5.3±1.9   5.3±1.6
    Serum albumin (g/dL)   4.0±0.3   3.9±0.3   4.0±0.3    4.3±0.4   4.0±0.3
    Alkaline phosphates (IU/L) 154.6±97.6   146.8±120.3   150.2±101.2  117.8±77.3 135.1±87.6
    high sensitivity CRP (log-transformed) -1.59±1.58  -1.10±1.70  -1.39±1.64   -2.06±1.00  -1.51±1.56
    iPTH (pg/mL)*,‡
616.5 
(329.0-1452.5)
822.5 
(689.0-2800.0)
660.0 
(329.0-2800.0)
641.0 
(331.5-1468.0)
666.0 
(329.0-2800.0)
Hemodialysis factors
    AV fistula, n (%)† 16 (42.1)   5 (55.6)  21 (44.7)   6 (60.0) 27 (47.4)
    AV graft, n (%)† 22 (57.9)   4 (44.4)  26 (55.3)   4 (40.0) 30 (52.6)
    Kt/V urea 1.44±0.21   1.51±0.26   1.48±0.24    1.45±0.31   1.47±0.29
    Dialysate calcium level (mEq/L)*    3.0 (2.5-3.5)     3.0 (2.5-3.5)        3 (2.5-3.5)    3.0 (2.5-3.5)    3.0 (2.5-3.5)
Medications, n (%)
    Calcitriol (iv or oral) 20 (54.1)   3 (33.3) 23 (48.9)   2 (20.0) 25 (43.8)
    Phosphate binder, total, n (%)   38 (100.0)   7 (77.8) 45 (95.7)   10 (100.0) 55 (96.5)
        Calcium-containing 21 (55.3)   4 (44.4) 25 (53.2)   5 (50.0) 30 (52.6)
        Sevelamer hydrochloride 16 (42.1)   2 (22.2) 18 (39.1)   6 (60.0) 24 (42.1)
        Lanthanum carbonate 2 (5.3)   1 (11.1) 3 (6.5)   2 (20.0) 5 (8.8)
MBP, mean blood pressure; PTG, parathyroid gland; iPTH, intact parathyroid hormone; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CRP, C-
reactive protein; AV, arteriovenous.
*Median with ranges.
†p<0.05 between responder vs. non-responder. 
‡p<0.05 between primary vs. secondary responder.
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because of hypocalcemia during treatment period. Although 
baseline iPTH levels and the largest length of the parathyroid 
gland were similar to those of responders, non-responders to 
cinacalcet were significantly younger (43.0± 7.7 vs. 
52.6±12.7, p=0.026), male (70.0% vs. 34.0%, p=0.041), and 
non-diabetic (100.0% vs. 72.3%, p<0.001) (Table 1). 
Corrected serum calcium levels also changed significant-
ly during cinacalcet treatment. Interestingly, a reduction in 
serum calcium concentration was observed in all patients 
regardless of iPTH response; even non-responders showed 
significantly decreased serum calcium levels with cinacal-
cet treatment. Repeated measures ANOVA was conducted 
to compare the changes of serum calcium levels between 
the three groups. Though calcium levels were reduced in all 
three groups (p<0.001), no intergroup differences were 
identified (Fig. 5, upper). In addition, although serum phos-
phorus levels also decreased with the use of cinacalcet, the 
difference was not statistically significant and probably due 
Twenty-eight (73.7%) patients reached the primary end 
point during the dose titration period, and 10 (26.3%) pa-
tients reached the primary end point during the maintenance 
period. The mean duration of treatment and cinacalcet dose 
required were 54 days and 37.5 mg, respectively. The medi-
an iPTH level decreased from 616.5 to 206.0 pg/mL (55.6% 
reduction) throughout the study period (Fig. 3). Although 
the primary end point was not reached in 9 patients (15.8%), 
these patients showed a reduction in plasma iPTH of at least 
30%, thus meeting criteria for the secondary end point. The 
median iPTH level of the secondary end point group de-
creased from 822.5 to 383.0 pg/mL, and the mean iPTH lev-
el decreased by 43.4% (Fig. 3). Among those patients who 
reached either the primary or secondary end point (all re-
sponders), an early response was observed in 30/47 (63.8%) 
patients, most of whom 27/30, 90.0% achieved the primary 
end point. Baseline clinical characteristics of patients with 
primary end point were similar to those with secondary end 
point, except that the former were significantly older (54.5± 
12.1 vs. 44.9±12.6, p=0.041), had lower iPTH levels (616.5 
vs. 822.5, p=0.001) and smaller parathyroid gland size 
(14.2 vs. 19.6 mm, p=0.024). The cumulative proportion of 
patients to reach primary or secondary end point per month 
is shown in Fig. 4.
No effect of cinacalcet was seen in 10/57 (17.5%) patients 
(non-responders); indeed, iPTH levels in these patients were 
not decreased, or even increased, during cinacalcet treatment. 
Among non-responders, 5 patients did not response to rela-
tively high-doses of cinacalcet (75-100 mg), however, the 
other five patients were treated with only 50 mg of cinacalcet 
Fig. 3. Effects of cinacalcet treatment on serum iPTH levels. In patients who achieved primary or secondary end point (responders), iPTH levels decreased 
significantly from baseline, whereas the levels were not changed or mildly increased in the non-responder group. iPTH, intact parathyroid hormone.
Visit 1 2 3 4 5 6 7 8 9 10
Primary 
end point
616.5 
(329-1452.5)
340.6 
(42-1274)
305.0 
(46-1109)
351.0 
(180-929)
431.5 
(80-938)
383.5 
(199-880)
374.0 
(285-564)
294.0 
(242-448)
262.3 
(100-400)
Secondary 
end point
822.5 
(689-2800)
652.0 
(393-2548)
637.5 
(319-1909)
585.0 
(366-1218)
545.0 
(314-1008)
460.5 
(334-587)
440 
(320-560)
410.0 
(315-500)
380.0 
(330-400)
Non-
responder
641.0 
(523-1468)
1012.0 
(551.9-1014)
844.5 
(571.7-1370)
900.5 
(547-1660)
899.5 
(587-1580)
930.5 
(510-1318)
1134.5 
(440-1397)
1063.0 
(458-1880)
1286.5 
(500-1890)
Fig. 4. The cumulative proportion of patients to reach primary or secondary 
end point per month.
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Fig. 5. Changes in serum calcium, phosphorus and calcium phosphorus products levels with cinacalcet treatment. Serum calcium levels were reduced in all 
three groups (p<0.001), however, the changes of serum phosphorus and calcium phosphorus products levels were statistically insignificant. Data were ana-
lyzed by repeated measures ANOVA. ANOVA, analysis of variance.
Visit 1 2 3 4 5 6 7 8 9 10
Primary 
end point
9.9 
(9.0-12.1)
9.3 
(7.7-11.8)
9.1 
(7.8-11.3)
8.4 
(7.8-10.6)
8.4 
(7.8-9.6)
8.8 
(8.1-9.7)
8.9 
(8.0-9.6)
8.8 
(8.7-9.6)
8.7 
(8.5-9.9)
Secondary 
end point
10.0 
(9.0-11.2)
9.2 
(8.2-10.8)
9.2 
(8.0-11.0)
8.9 
(8.3-9.5)
8.7 
(8.5-9.6)
9.0 
(8.1-10.0)
8.8 
(8.1-10.0)
8.7 
(8.5-9.5)
8.6 
(7.8-9.0)
Non-
responder
10.7 
(9.0-12.8)
9.1 
(8.7-11.3)
8.6 
(8.3-10.4)
9.0 
(8.3-9.9)
8.8 
(7.2-10.0)
8.9 
(8.8-9.9)
8.9 
(8.6-9.6)
8.9 
(8.2-9.1)
9.1 
(8.8-10.5)
Visit 1 2 3 4 5 6 7 8 9 10
Primary 
end point
5.2 
(2.1-8.4)
5.2 
(2.4-7.2)
5.1 
(2.5-7.9)
5.0 
(2.2-6.9)
5.1 
(2.8-7.3)
5.2 
(3.1-7.3)
5.1 
(3.0-7.0)
5.0 
(2.9-6.1)
4.0 
(2.0-6.0)
Secondary 
end point
6.3 
(2.7-8.9)
4.9 
(3.1-7.5)
5.6 
(4.3-6.9)
5.1 
(4.1-6.7)
5.2 
(3.6-6.4)
5.2 
(4.0-6.3)
4.1 
(3.2-5.1)
4.1 
(3.2-4.6)
4.0 
(3.8-4.2)
Non-
responder
5.3 
(3.0-8.1)
7.1 
(5.3-9.7)
6.5 
(5.2-8.3)
6.7 
(4.7-9.8)
6.0 
(4.4-9.0)
6.2 
(3.6-7.6)
6.4 
(3.0-7.9)
6.5 
(4.2-7.8)
6.4 
(4.3-7.8)
Visit 1 2 3 4 5 6 7 8 9 10
Primary 
end point
52.4 
(22-70.7)
52.3 
(21.6-67.3)
46.5 
(26.2-73.4)
42.7 
(23.4-66.9)
41.3 
(23.0-64.7)
49.0 
(27.6-63.5)
51.5 
(26.7-61.6)
50.5 
(25.2-57.4)
52.0 
(26.0-57.0)
Secondary 
end point
55.0 
(26.5-75.1)
41.8 
(28.8-63.75)
40.0 
(26.5-62.6)
38.7 
(20.2-68.7)
47.3 
(30.6-75.1)
50.0
 (25.2-69.0)
46.0 
(25.6-70.1)
44.0 
(22.5-68.5)
48.0 
(22.0-68.5)
Non-
responder
68.8 
(32.4-77.3)
66.8 
(54.4-80.2)
60.6 
(49.0-75.5)
58.4 
(43.2-78.6)
53.7 
(38.8-79.2)
54.5 
(33.1-67.6)
62.5 
(27.6-69.2)
62.4 
(35.3-69.4)
60.5 
(35.3-81.9)
7.0
0
20
8.0
2
30
7.5
1
9.0
4
8.5
3
40
10.0
6
60
9.5
5
50
11.0
7
10.5
12.0
9
80
11.5
8
70
12.5
10
13.0
11
90
1
1
1
2
2
2
3
3
3
4
4
4
5
5
5
6
6
6
7
7
7
8
8
8
9
9
9
10
10
10
Visit
Visit
Visit
Secondary end point 
Secondary end point
Secondary end point
Primary end point 
Primary end point 
Primary end point 
Non-responder 
Non-responder 
Non-responder 
Dose titration
Dose titration
Dose titration
Maintenance
Maintenance
Maintenance
Corrected calcium (mg/dL)
Phosphorus (mg/dL)
Calcium-phosphorus product (mg2/dL2)
Importance of Early Response to Cinacalcet
Yonsei Med J   http://www.eymj.org   Volume 54   Number 2   March 2013 459
observation was statistically insignificant (p=0.101). Ac-
cording to multivariate analysis, lower baseline iPTH levels, 
diabetes, and the presence of an early response were signifi-
cant clinical factors affecting achievement of iPTH end 
points by cinacalcet (Table 2, Supplemental Fig. 2). The re-
sponse rates according to the range of baseline iPTH level 
are shown in Fig. 6. The presence of early response was as-
sociated with about 20-fold higher probability to achieve 
target iPTH level. In addition, diabetic patients showed 
more favorable response to cinacalcet therapy. In fact, near-
ly all the diabetic patients reached the primary end point 
(Fig. 7).
Safety
Cinacalcet, at doses ranging from 25 to 100 mg once per day, 
was generally well tolerated, and no patient experienced a se-
rious adverse event during the study period. Adverse events 
to concomitant changes in phosphate binder and reductions 
of vitamin D agents over the study period (Fig. 5, middle). 
The changes of calcium-phosphorus products were statisti-
cally insignificant (Fig. 5, lower).
Clinical factors that influence the degree of response to 
cinacalcet
We investigated clinical factors predicting a better response 
to cinacalcet treatment using logistic regression analysis. In 
univariate analysis, older age, diabetes, lower baseline iPTH 
levels, and an early response to cinacalcet were significantly 
associated with the achievement of the primary end point. 
As patients get older, the median iPTH level was decreased, 
therefore, older patients seem to have better response to 
cinacalcet (Supplemental Fig. 1). A larger size detected for 
the parathyroid gland appeared to negatively influence the 
possibility of reaching the primary end point, however, this 
Supplemental Fig. 1. Median iPTH levels and response rate to cinacalcet according to age group. iPTH, intact parathyroid hormone.
Table 2. Clinical Factors Influencing Achievement of the Primary End Point with Cinacalcet Treatment
Unadjusted Adjusted
OR (95% CI) p value OR (95% CI) p value
All patients
    Age (per 1 yr)   1.10 (1.03-1.17) 0.005   1.07 (0.99-1.17) 0.090
    Gender (male vs. female)   0.65 (0.21-1.98) 0.446 - -
    Diabetes (presence)   8.31 (0.99-69.67) 0.051 46.45 (1.92-1125.6) 0.018
    Duration of dialysis (per 1 yr)   0.99 (0.92-1.09) 0.984 - -
    Size (per 1 mm)   0.92 (0.84-1.10) 0.101 - -
    Baseline iPTH (per 10 pg/mL)   0.98 (0.96-0.99) 0.027   0.96 (0.93-0.99) 0.015
    Presence of early response* 13.10 (3.17-54.08) <0.001 21.54 (2.94-157.7) 0.003
Non-diabetic patients only
    Age   1.10 (1.01-1.15) 0.021   1.07 (0.98-1.16) 0.115
    Gender (male vs. female)   0.62 (0.18-2.11) 0.449 - -
    Size (per 1 mm)   0.92 (0.83-1.03) 0.162 - -
    Baseline iPTH (per 10 pg/mL)   0.97 (0.95-0.99) 0.048   0.96 (0.93-0.99) 0.012
    Presence of early response* 13.57 (3.00-61.59) 0.001 20.44 (2.81-148.96) 0.003
iPTH, intact parathyroid hormone; OR, odds ratio; CI, confidence interval.
*Decrease of iPTH levels >50% from baseline within 4 weeks.
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that occurred with ≥5% frequency were nausea/vomiting 
(21.1%), dyspepsia (14.0%), myalgia/arthralgia (10.5%), 
constipation (7.0%), febrile sensation (7.0%), and diarrhea 
(5.3%) (Table 3). Most of these events occurred in a dose-
independent manner and were mild to moderate in severity. 
These symptoms either resolved spontaneously or improved 
quickly with intervention. In our study, there was no case of 
albumin-corrected calcium level <7.5 mg/dL. However, 15 
patients (26.3%) experienced the decrease of calcium <8.0 
mg/dL during study period.
DISCUSSION
Currently, cinacalcet is the only available potent calcimi-
metic for the management of SHPT.3 Previous randomized 
controlled studies have demonstrated its safety and efficacy 
for controlling serum iPTH, calcium, and phosphorus lev-
els compared to conventional methods.2,4,14 Moreover, re-
cent observational studies suggest the benefit of cinacalcet 
treatment in reducing all-cause and cardiovascular mortali-
ty in dialysis patients.1 However, not all patients have a fa-
vorable response to cinacalcet or are able to tolerate the 
drug. In this study, therefore, we prospectively investigated 
67 hemodialysis patients from seven medical centers in Ko-
rea and evaluated the response rate to cinacalcet. Depend-
Supplemental Fig. 2. Clinical factors affecting achievement of iPTH target. iPTH, intact parathyroid hormone; DM, diabetes mellitus.
Fig. 6. The response rates according to baseline iPTH level. iPTH, intact 
parathyroid hormone.
Fig. 7. Response rate to cinacalcet according to diabetes. Diabetic patients 
showed a more favorable response to cinacalcet compared to non-diabet-
ics (p<0.001).
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nodular hyperplasia.21,22 Therefore, more large-scale study 
is required to ascertain detailed characteristics of these re-
sponder/non-responder groups. In our study, nevertheless, 
lower baseline iPTH level was significantly associated with 
more favorable outcome to cinacalcet treatment. Similarly, 
a larger size parathyroid gland appeared to negatively influ-
ence the possibility of reaching the primary end point, al-
though statistically insignificant. In line with our present 
finding, Yamamoto, et al.23 recently found that two or more 
enlarged parathyroid glands might be a significant risk of 
poor response to cinacalcet treatment. 
In this respect, it is of particular interest to note that an ear-
ly decrease in iPTH may be an important clue for predicting 
better response to cinacalcet. More than 60% of the respond-
ers in our study showed remarkable decrease of iPTH levels 
by 50% or more within 1 month after the administration of 
cinacalcet, and most patients with an early response had ex-
cellent outcomes. Moreover, multivariate logistic regression 
analysis revealed that the efficacy of cinacalcet in iPTH tar-
get achievement was significantly associated with the pres-
ence of an early response, which was consistent regardless of 
the presence of diabetes. In accordance with our data, a re-
duction in iPTH levels after 3 months of treatment with rela-
tively lower doses has been reported as a prognostic marker 
of good response to cinacalcet treatment.24 Another impor-
tant finding in our study was that diabetic patients showed a 
more favorable response to cinacalcet compared to non-dia-
betics (p<0.001). The presence of diabetes was associated 
with 46-fold increased probability to achieve primary end 
point, and all the non-responders were non-diabetics, sug-
gesting the possibility that these results are due to unique 
characteristics of renal osteodystrophy in diabetic patients. 
Among diabetic patients, it is well known that high-turnover 
bone disorders are distinctly uncommon, while low-turnover 
bone disorders are more frequent.25,26 Bone morphology in 
diabetic patients is characterized by lower trabecular and 
ing on the degree of response, patients were divided into 
two groups: responders (further subdivided to patients with 
primary or secondary end points), and non-responders.  
One major finding of this study was that more than 80% 
of patients showed a good response to cinacalcet, with the 
majority achieving the iPTH target levels recommended by 
the Kidney Disease Outcomes Quality Initiative.19 Although 
only 20% of responders reached secondary end point, their 
baseline iPTH levels were significantly higher than those 
who met the primary end point, and furthermore, six pa-
tients could not receive full-doses of cinacalcet because of 
hypocalcemia. Therefore, patients with hypocalcemia are 
expected to have insufficient doses of cinacalcet. Treatment 
over longer durations and with higher doses may lead to the 
primary end point in these patients as well.
On the contrary, cinacalcet had no impact on iPTH re-
duction in about 17% of patients. Despite half of these pa-
tients could not receive a sufficient dose because of hypocal-
cemia, the remaining half were resistant to full-doses of 
cinacalcet therapy. Except the fact that non-responders tend-
ed to be younger and less frequently diabetic, their baseline 
characteristics were similar to responders. Even baseline 
iPTH level and the largest diameter of the parathyroid gland 
were also comparable between the two groups. Therefore, 
the prediction of future response rate with baseline charac-
teristics seems to be difficult. However, this finding is not so 
surprising because the efficacy of cinacalcet for lowering 
iPTH levels has been reported to be unaffected by disease 
severity, as judged by baseline iPTH values or adenoma for-
mation. For instance, Frazão, et al.8 reported that cinacalcet 
could reduce plasma iPTH levels irrespective of the severity 
of SHPT, and Shoback, et al.20 demonstrated the efficacy of 
cinacalcet in patients with primary hyperparathyroidism 
with adenoma. In addition, excellent long-term efficacy in 
reducing serum iPTH levels was observed also in patients 
with severe, refractory tertiary hyperparathyroidism with 
Table 3. Drug-Related Adverse Events
Cinacalcet dose (mg)
Total (%) 25 50 75 100
Nausea/vomiting 12 (21.1) 3 5 2 2
Dyspepsia   8 (14.0) 1 3 3 1
Constipation 4 (7.0) 1 2 1 -
Diarrhea 3 (5.3) - 1 1 1
Febrile sensation 4 (7.0) 1 1 2 -
Myalgia/arthralgia   6 (10.5) 1 2 3 -
Others* 5 (8.8) 1 4 - -
*Increased blood pressure (n=1), headache (n=1), dizziness (n=2), and skin rash (n=1).
Jwa-Kyung Kim, et al.
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line iPTH levels and the presence of diabetes also seem to 
be important factors for predicting the effect of cinacalcet.
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